Thursday , July 20 2017
Home / HIV/AIDS

HIV/AIDS

Gilead Submits Application for Investigational Triple Therapy HIV Treatment to the FDA

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25 …

Read More »

Gilead’s Investigational HIV Combo Meets Primary Endpoint in Four Late-Stage Studies

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority. Three of the …

Read More »

Path to End HIV Could Be Within Reach for United States in Next Decade

The United States could be on track within the next decade to see significant steps towards ending the HIV epidemic in this country, suggests new research from the Johns Hopkins Bloomberg School of Public Health and Brigham and Women’s Hospital. The researchers say their findings reveal that, with adequate commitment, …

Read More »

FDA Grants Tentative Approval to Mylan’s HIV Drug Combo Under PEPFAR

HERTFORDSHIRE, England and PITTSBURGH, March 20, 2017 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Efavirenz, Lamivudine and …

Read More »

Gilead Presents Positive Mid-Stage Data for its Investigational HIV Candidate Bictegravir

SEATTLE–(BUSINESS WIRE)–Feb. 13, 2017– Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from a Phase 2 study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) versus dolutegravir (50 mg) (DTG) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) in treatment …

Read More »

Researchers Use CRISPR to Accelerate Search for HIV Cure

Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection. The team built a high-throughput cell-editing platform using a variant of CRISPR/Cas9 technology that allowed them to test how …

Read More »

New Nanomedicine Approach Aims to Improve HIV Drug Therapies

New research led by the University of Liverpool aims to improve the administration and availability of drug therapies to HIV patients through the use of nanotechnology. The research, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, examined the use …

Read More »

Aphios to Develop Cure for HIV/AIDS Using Combination Drugs in Targeted ‘Nanosomes’ Nanoparticles

WOBURN, Mass.–(BUSINESS WIRE)–Aphios Corporation today announced that it plans to continue its research to develop a cure for HIV/AIDS using combination drugs in targeted ‘nanosomes’ nanoparticles with recent funding from the National Institute of Allergy and Infectious Diseases (NIAID), NIH. Currently, about 35 million people have died from AIDS and …

Read More »

Genmab Licenses DuoBody Technology Platform to Gilead for Bispecific Antibody Against HIV

Copenhagen, Denmark; August 10, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has entered an agreement to grant Gilead Sciences, Inc. an exclusive license and an option on a second exclusive license, to use the DuoBody® technology platform to create and develop bispecific antibody candidates for a therapeutic …

Read More »

First Next-Generation Sequencing Test for HIV Drug Resistance Could Help Fight AIDS Worldwide

PHILADELPHIA, Aug. 3, 2016 /PRNewswire-USNewswire/ — Research announced today at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo demonstrates that a first-of-its-kind next-generation sequencing test can detect HIV drug resistance mutations that conventional tests fail to identify. This test could play a critical role in helping clinicians to …

Read More »